{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268146","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.402324+00:00","generated_at":"2026-05-16T23:54:02.920650+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MBX posts positive Phase 2 results for canvuparatide; Q3 net loss $21.6M; cash $391.7M","bullets":["Q3 2025 net loss $21.6M vs $18.1M YoY; cash and equivalents $391.7M (includes $200M offering proceeds) funding into 2029.","Positive Phase 2 topline: 63% of canvuparatide-treated patients met composite endpoint at 12 weeks; 79% at 6 months in open-label extension.","Dosed first participant in Phase 1 trial of MBX 4291 (GLP-1/GIP co-agonist) for obesity; results from MAD portion expected Q4 2026.","Dosed first patient in Phase 2a trial of imapextide for post-bariatric hypoglycemia; results expected Q2 2026.","Director changes: James Cornelius resigned Oct 31; Steven Hoerter appointed executive chairman effective Nov 6, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268146","json":"https://secwatch.observer/filing/0001193125-25-268146.json","markdown":"https://secwatch.observer/filing/0001193125-25-268146.md","text":"https://secwatch.observer/filing/0001193125-25-268146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000119312525268146/0001193125-25-268146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000119312525268146/mbx-20251031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:54:02.920650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}